180 related articles for article (PubMed ID: 10945566)
1. Tenascin patterns of expression in duct carcinoma in situ of the breast.
Iskaros BE; Sison CP; Hajdu SI
Ann Clin Lab Sci; 2000 Jul; 30(3):266-71. PubMed ID: 10945566
[TBL] [Abstract][Full Text] [Related]
2. Ultrastructure of the periductal area of comedo carcinoma in situ of the breast.
Tang P; Teichberg S; Roberts B; Hajdu SI
Ann Clin Lab Sci; 2001 Jul; 31(3):284-90. PubMed ID: 11508833
[TBL] [Abstract][Full Text] [Related]
3. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
7. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
8. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.
Claus EB; Chu P; Howe CL; Davison TL; Stern DF; Carter D; DiGiovanna MP
Exp Mol Pathol; 2001 Jun; 70(3):303-16. PubMed ID: 11418009
[TBL] [Abstract][Full Text] [Related]
9. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas.
de Mascarel I; MacGrogan G; Mathoulin-Pélissier S; Soubeyran I; Picot V; Coindre JM
Cancer; 2002 Apr; 94(8):2134-42. PubMed ID: 12001109
[TBL] [Abstract][Full Text] [Related]
10. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
Vogl G; Dietze O; Hauser-Kronberger C
Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
[TBL] [Abstract][Full Text] [Related]
12. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
[TBL] [Abstract][Full Text] [Related]
13. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of in situ carcinoma of the breast.
Eusebi V; Feudale E; Foschini MP; Micheli A; Conti A; Riva C; Di Palma S; Rilke F
Semin Diagn Pathol; 1994 Aug; 11(3):223-35. PubMed ID: 7831534
[TBL] [Abstract][Full Text] [Related]
16. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
[TBL] [Abstract][Full Text] [Related]
17. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
18. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma.
Pawlik TM; Perry A; Strom EA; Babiera GV; Buchholz TA; Singletary E; Perkins GH; Ross MI; Schecter NR; Meric-Bernstam F; Ames FC; Hunt KK; Kuerer HM
Cancer; 2004 Feb; 100(3):490-8. PubMed ID: 14745864
[TBL] [Abstract][Full Text] [Related]
19. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
20. Tenascin-A marker for the malignant potential of preinvasive breast cancers.
Goepel C; Buchmann J; Schultka R; Koelbl H
Gynecol Oncol; 2000 Dec; 79(3):372-8. PubMed ID: 11104607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
